Related Experiment Video
Updated: Jan 27, 2026

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
Published on: December 9, 2016
Molecular insights into cancer drug resistance from a proteomics perspective
Yao An1,2, Li Zhou1, Zhao Huang1
1a West China School of Basic Medical Sciences & Forensic Medicine , Sichuan University , Chengdu , PR China.
Introduction:
Resistance to chemotherapy and development of specific and effective molecular targeted therapies are major obstacles facing current cancer treatment. Comparative proteomic approaches have been employed for the discovery of putative biomarkers associated with cancer drug resistance and have yielded a number of candidate proteins, showing great promise for both novel drug target identification and personalized medicine for the treatment of drug-resistant cancer. Areas covered: Herein, we review the recent advances and challenges in proteomics studies on cancer drug resistance with an emphasis on biomarker discovery, as well as understanding the interconnectivity of proteins in disease-related signaling pathways. In addition, we highlight the critical role that post-translational modifications (PTMs) play in the mechanisms of cancer drug resistance. Expert opinion: Revealing changes in proteome profiles and the role of PTMs in drug-resistant cancer is key to deciphering the mechanisms of treatment resistance. With the development of sensitive and specific mass spectrometry (MS)-based proteomics and related technologies, it is now possible to investigate in depth potential biomarkers and the molecular mechanisms of cancer drug resistance, assisting the development of individualized therapeutic strategies for cancer patients.
Insights
Proteomics research is uncovering biomarkers for cancer drug resistance. Understanding protein changes and modifications is crucial for developing targeted therapies for drug-resistant cancers.
Area of Science:
- Oncology
- Proteomics
- Biomarker Discovery
Background:
- Cancer treatment faces significant challenges from drug resistance and the need for targeted therapies.
- Comparative proteomics has identified potential biomarkers for cancer drug resistance, aiding drug target discovery and personalized medicine.
Purpose of the Study:
- To review recent advances and challenges in proteomics for cancer drug resistance research.
- To emphasize biomarker discovery and understanding protein interactions in signaling pathways.
- To highlight the role of post-translational modifications (PTMs) in drug resistance mechanisms.
Main Methods:
- Review of current literature on proteomics studies in cancer drug resistance.
- Analysis of mass spectrometry (MS)-based proteomics technologies.
- Focus on biomarker identification and PTMs in drug-resistant cancer.
Main Results:
- Proteomics studies have identified candidate proteins as biomarkers for drug resistance.
- Post-translational modifications (PTMs) play a critical role in the mechanisms of cancer drug resistance.
- Advances in MS-based proteomics enable in-depth investigation of resistance mechanisms.
Conclusions:
- Deciphering proteome profiles and PTMs is key to understanding cancer treatment resistance.
- Proteomics facilitates the discovery of biomarkers and molecular mechanisms for individualized cancer therapies.
- This research supports the development of personalized therapeutic strategies for drug-resistant cancer patients.
More Related Videos
Related Concept Videos
Treatment Resistant Cancers
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Psychodynamic Perspectives on Personality
Psychodynamic theorists argue that unconscious...
Molecular Models
The Behavioral Perspective on Personality
Criticisms of the Evolutionary Perspective
Evolutionary psychology provides one explanation for these findings, suggesting...

